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Case presentations
Patient 1. A 28-year-old black Haitian man was admitted to Jackson
Memorial Medical Center for the first time for evaluation of fever of one
month's duration. He also complained of epigastric pain, nausea, and
vomiting. When the patient had come to the United States 5 years
earlier, he was found to have pulmonary tuberculosis and was treated
with antituberculous agents for 12 months; he spent 3 months in a
quarantine hospital in Florida. The patient was married and the father of
3 children. He was a dock worker until 3 months prior to admission. He
denied previous renal disease, rheumatic fever, diabetes mellitus, or
hypertension. He denied having any risk factors for infection with the
human immunodeficiency virus, including transfusions, homosexuality,
or intravenous drug use.
Physical examination revealed a thin black male with a temperature
of 38°C, a blood pressure of 110/80 mm Hg, a regular pulse rate of 110
beats/mm, and a respiratory rate of 22 breaths/mm. He had periorbital
edema and black, hyperpigmented, fiat lesions over the forehead and
face. Pulmonary examination revealed diffuse coarse rhonchi, more
prominent over the left lung field than the right, with a left pleural
friction rub. There was a soft, nonradiating systolic ejection murmur
over the apex. The abdomen was distended. The edge of the liver was
palpable, smooth, and tender. The epigastrium felt full and was painful
on deep palpation. Bowel sounds were normal. Except for prominent
inguinal adenopathy bilaterally, other lymph nodes were not palpable.
Trace ankie edema was present. Neurologic examination was normal.
On admission, the hematocrit was 33% and white blood cell count
8200/mm3 with 64% neutrophils, 20% band forms, 11% lymphocytes,
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3% monocytes, and 2% eosinophils. Platelets were 169,000/mm3. The
erythrocyte sedimentation rate was 116 mm/hr. Sickle cell preparation
was negative. Blood chemistry evaluation revealed: serum sodium, 134
mEqfliter; chloride, 114 mEq/liter; potassium, 4.5 mEq/liter; total CO2.
15 mEq/liter; BUN, 69 mg/dl; creatinine, 5.3 mg/dl; calcium, 7.8 mg/dl;
phosphorus, 7.0 mg/dl; total protein, 6.3 g/dl; albumin, 1.6 g/dl; and
amylase, 215 IU. Liver function tests were normal. Complement
proteins C3 and C4 were normal. The urine had a pH of 5.0, a specific
gravity of 1.013, 3+ protein, and 25 to 50 red blood cells and ito 5 white
blood cells/high-power field. No casts were seen. A plain chest radio-
graph revealed diffuse bilateral infiltrates, a patchy density in the left
lower lobe, cystic changes in both apices, and mediastinal changes
consistent with enlarged lymph nodes. Several blood and urine cultures
were negative. Sputum examination, however, revealed acid-fast ba-
cilli. Antituberculous therapy was initiated with isoniazid, rifampin, and
ethambutol. A 24-hour collection provided 1500 ml of urine containing
6.9 g of protein and 1.1 g of creatinine. Creatinine clearance was 8.9
mI/mm.
During his hospitalization, the patient developed intermittent fevers
up to 41°C. Ultrasonographic examination of the abdomen showed
numerous enlarged retroperitoneal and periportal lymph nodes, hepato-
megaly without focal lesions, a normal pancreas, and large echogenic
kidneys (14 cm each longitudinally) without evidence of outflow ob-
struction. A gallium scan revealed diffuse uptake in the right lung and
abnormal accumulation of the radiotracer in the upper mediastinum and
paraortic region. Renal biopsy showed focal segmental glomeruloscle-
rosis with an intense visceral epithelial cell reaction and modest
segmental mesangial proliferation in the glomeruli; an abundant inter-
stitial infiltrate contained lymphocytes and plasmacytes; the proximal
tubules contained numerous hyaline droplets and focal areas of regen-
eration; tubules were markedly dilated and filled with large casts. A skin
biopsy revealed acanthosis and parakeratosis with postinflammatory
hyperpigmentation but no evidence of Kaposi's sarcoma. Serologic
studies were positive for hepatitis B core antibodies, fluorescent
treponema antibody (2+), and HIV-1 antibodies (by ELISA test con-
firmed by Western blot), and negative for antinuclear antibody and
hepatitis-B surface antigen. The CD-4 to CD-8 lymphocyte ratio was
0.42.
Six days after admission, the BUN was 103 mg/dl and the serum
creatinine 9 mg/dl; hemodialysis was initiated. Twelve days after
admission, a radiologically guided biopsy of the periportal lymph nodes
disclosed pus that stained positive for acid-fast bacilli. The organisms
later were identified as Mycobacterium gordonae. Bronchoscopy
showed no endobronchial lesions and revealed Candida albicans in
bronchial washings but no Pneumocystis carinii.
The patient was hemodialyzed 9 times in 15 days. He then refused
further dialysis and expressed the wish to return to his native country.
He left for Haiti after 25 days of hospitalization. No followup is
available.
Patient 2. A 41-year-old black Jamaican woman was hospitalized at
Jackson Memorial Medical Center because of renal failure. She com-
plained of nausea, vomiting, intermittent fevers, sweats, and increasing
pedal and penorbital edema for 2 weeks. The medical history included
2 previous hospital admissions. Seventeen months earlier, the patient
had been admitted for a viral syndrome with arthralgias, fever, metror-
rhagia, and headaches. Her blood pressure was 130/70 mm Hg and her
weight was 136 lbs. The blood urea nitrogen was 10 mg/dl and the serum
creatinine 0.9 mg/dl. Serum total protein was 6.4 g/dl and albumin was
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3.9 g/dl. Proteinuria was 1+. Evaluation included a negative workup for
possible vasculitis or hemolysis. She was discharged and given iron
supplements; the diagnosis was iron-deficiency anemia. At discharge,
the BUN was 5 mg/dl and the serum creatinine 0.5 mgldl.
Fifteen months later she was readmitted for 9 days with a history of
cough productive of scanty sputum, intermittent fevers, fatigue, and
weight loss of 14 lbs in 3 months. No peripheral edema was present. A
plain chest film revealed bilateral interstitial pneumonia. Serology was
positive for HIV-l infection by ELISA and Western blot. The patient
denied both a history of intravenous drug use and receipt of blood
transfusions, Her former husband was an intravenous drug user. An
extensive workup including repeated sputum testing, bronchoscopy
with biopsy, and special cytologic preparations for acid-fast bacilli and
Pneuinocystis carinii failed to establish a diagnosis. Blood and urine
cultures remained negative. No granulomas were identified in the bone
marrow. At admission, the BUN was 14 mgldl and serum creatinine 2.0
mg/dl. Urine showed trace and 1 + proteinuria and was normal on
microscopic examination. A renal ultrasonogram showed diffusely
hyperechogenic, 11 cm kidneys. She was discharged on an empiric
regimen of trimethopnmlsulfamethoxazole and ketoconazole; the BUN
was 5 mg/dl and serum creatinine was 1.5 mg/dl.
The patient was readmitted 6 weeks later, when the BUN increased
to 78 mg/dl and serum creatinine to 11.4 mg/dl. She denied diarrhea,
hematuria, melena, jaundice, skin rashes, dysphagia, rheumatic fever,
and hepatitis. Physical examination revealed an afebrile female weigh-
ing 116 ibs; the blood pressure was 150/86 mm Hg; no orthostatic
hypotension was present; and the pulse rate was 80 beats/mm. She had
periorbital edema, anicteric sclerae, pale conjunctivae, and small pos-
terior cervical nodes (<.5 cm). Oral thrush was not present. The
cardiopulmonary examination was unremarkable, She had 3+ pretibial
pitting edema. Neurologic examination was normal. Pertinent labora-
tory values on admission included: hematocrit, 16%; white blood cell
count, 3900 mm3 with 64% neutrophils, 18% band forms, and 18%
lymphocytes; and platelets, 248,000 per mm3. Erythrocyte sedimenta-
tion rate was 106 mm/hr. Serum sodium was 137 mEq/liter; potassium,
5.3 mEq/liter; chloride, 104 mEq/liter; total C02, 20 mEq/liter; calcium,
8.6 mgldl; phosphorus, 6.8 mg/dl; uric acid, 9.9 mg/dl; total protein, 6.3
gIdl; and albumin, 2.5 g/dl. Liver function tests were normal. Hepatitis
B serology and a second vasculitis screen were negative. Urinalysis
showed 3+ protein, 25 to 50 white blood cells/high-power field, and no
casts. A 24-hour urine collection contained 12.7 g of protein and 0.72 g
of creatinine. Creatinine clearance was less than 5 mI/mm. Repeat renal
sonogram showed 11.0 and 12.1 cm hyperechogenic kidneys with no
evidence of hydronephrosis. A renal biopsy documented focal segmen-
tal glomerulosclerosis with dilated tubules containing large casts. The
patient was transfused and hemodialysis was begun one day after
admission. She was discharged 2 weeks later to the chronic outpatient
hemodialysis unit.
On maintenance hemodialysis, she maintained a "dry weight" of 100
5 lbs over the next 3 months during which several hospital admissions
were needed for urinary tract infections and for arteriovenous access
failures. Three months after her first hemodialysis, she developed an
altered mental status and was found to have Proteus mirabilis and
Cryptococcus neoformans sepsis. She died one month later with
cryptococcal meningitis despite antifungal therapy.
Discussion
DR. JACQUES J. B0uRG0IGNIE (Chief of Nephrology and
Professor of Medicine, University of Miami School of Medi-
cine, Miami, Florida): These two patients illustrate two typical
modes of presentation of patients with human immunodefi-
ciency virus type 1-associated nephropathy (HIVN). The first
patient presented with a nephrotic syndrome and rapidly pro-
gressive azotemia and required hemodialysis within weeks. The
second patient developed more insidious renal disease with
minimal proteinuria and a serum creatinine that progressed
from 0.5 to 1.5 mg/dl in 14 months. Thereafter it increased to
11.4 mgldl in less than 2 months with proteinuria of 12.7 g/24 hr.
Neither patient was at risk of HIV infection from homosex-
uality, intravenous drug use, or blood transfusion. Neverthe-
Table 1. Prevalence of electrolyte disorders in patients with AIDS
Electrolyte alteration Percentage
Hyponatremia
Hyperkalemia
Hypocalcemia
Hypercalcemia
Hypouricemia
Hyperuricemia
31—52
16
majority
rare
22
frequent
less, one patient had acquired immunodeficiency syndrome
(AIDS) and the other AIDS-related complex (ARC) (because of
constitutional symptoms) at the time of diagnosis. Both patients
were black and had little evidence of hypertension. They had
normal-sized or enlarged, hyperechogenic kidneys. Renal bi-
opsy was characteristic of HIV nephropathy. Both patients
were started on chronic hemodialysis. One patient elected to
discontinue dialytic therapy after 2 weeks; the other patient
died within 3 months despite provision of supportive hemodi-
alysis.
More than 115,000 patients with AIDS have been reported to
the Centers for Disease Control in the United States; more than
67,000 of these have died by November 1989. Considering the
spread of the AIDS epidemic worldwide, the number of patients
with this disease is at least double this number [1].
Infections and neoplasms are the dominant clinical manifes-
tations of AIDS in patients with the human immunodeficiency
virus type 1 (HIV-l, formerly called LAV/HTLV-III). More
important for this Forum, renal complications and electrolyte
disorders have been increasingly recognized, as exemplified by
the dramatic renal manifestations associated with HIV- 1 infec-
tion in patients 1 and 2. Typically, electrolyte and acid-base
disorders and acute renal failure occur in patients with the
full-blown clinical disorder of AIDS. But HIVN is often seen in
patients with AIDS-related complex, that is, in patients with
oral thrush or with constitutional symptoms (intermittent fever,
weight loss, diarrhea, generalized lymphadenopathy), before
the opportunistic infections and/or neoplasms typical of AIDS
are diagnosed or in otherwise asymptomatic HIV- 1 carriers [21.
I first will discuss fluid and electrolyte problems and renal
failure in patients with AIDS before turning to the HIVN seen
in patients infected with HIV-l.
Acid-base and electrolyte disturbances
Simple and mixed (double or triple) acid-base disturbances
and virtually all types of electrolyte disorders are observed in
AIDS patients with gastrointestinal disorders (vomiting, diar-
rhea, malabsorption, malnutrition), hemodynamic instability
(volume depletion, hypotension, sepsis), or respiratory, central
nervous system, and/or renal failure. In contrast to what is seen
in AIDS patients, the frequency and severity of electrolyte
abnormalities in patients with ARC is very low [3]. Common
electrolyte disorders and their prevalence in AIDS patients are
listed in Table 1. I have obtained much of these data from
abstracts presented at the 1988 meeting of the American Society
of Nephrology, and the data accordingly are preliminary.
Hyponatremia, the most common electrolyte abnormality, is
associated with volume depletion in the majority of patients (as
many as 88%) and can be corrected readily by saline adminis-
tration [4—61. In the absence of an evident source of fluid loss,
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volume depletion usually is related to renal salt wasting with an
inappropriately high urinary sodium concentration. Adrenal
insufficiency can cause hyponatremia in a minority of patients
(hyperkalemic patients with low ACTH stimulation test),
whereas other defects in tubular sodium reabsorptive capacity
have been postulated in the majority of patients (normo- or
hypokalemic patients with normal ACTH stimulation test) [4, 5,
7].
In euvolemic patients with a "high" urinary sodium concen-
tration, hyponatremia is compatible with nonosmolar, inappro-
priate secretion of antidiuretic hormone [4—6, 8], as might be
anticipated in patients with pulmonary or central nervous
system pathology. Hyponatremia in hypervolemic patients is
dilutional in origin as a result of excess free-water intake in the
presence of renal insufficiency [4].
The potential for adrenal insufficiency (Addison's disease) in
patients with AIDS was recognized early in the AIDS epidemic
because of frequent autopsy findings of adrenal necrosis related
to cytomegalovirus, mycobacterium, or cryptococcal infection
[9—il]. Overt adrenal insufficiency is relatively rare, however,
when compared with the frequent autopsy findings of adrenali-
tis and adrenal necrosis. This discrepancy has been ascribed to
the fact that adrenal cortical necrosis in patients with AIDS
usually involves less than 70% of the adrenal glands (allowing
for adequate production of cortisol by the uninvolved tissue).
Nevertheless, even though overt adrenal insufficiency is infre-
quent, an inadequate cortisol response to ACTH stimulation is
common in patients with AIDS [12, 13]. Adrenal function may
be normal under basal conditions, but the adrenals have a
limited functional reserve, and adrenal insufficiency may be-
come clinically evident under stressful situations.
In vitro, the antifungal agent ketoconazole (widely used in
AIDS patients) has been shown to inhibit steroid production
[141. In vivo, however, ketoconazole has rarely been demon-
strated to cause glucocorticoid insufficiency [15]. On the other
hand, ketoconazole has a greater selectivity for inhibiting
androgen production and can induce gynecomastia in AIDS
patients receiving high-dose, prolonged treatment [14]. Hypo-
adrenalism also can be the consequence of selective partial
hypopituitarism with subnormal ACTH release in patients with
AIDS [13].
Hyperkalemia has been reported in 16% of patients with
AIDS [6]. The increased serum potassium may be the conse-
quence of Addison's disease, or it can result from hyporenin-
ernie hypoaldosteronism in the absence of nephropathy [16].
Mild to moderate hypocalcemia, generally associated with
hypoalbuminemia, affects a majority of AIDS patients [3, 6].
The hypoalbuminemia, however, does not always fully account
for the hypocalcemia [3, 6]. Conversely, hypercalcemia has
been reported in association with granulomatous diseases,
disseminated cytomegalovirus infection, and with human T-cell
leukemia associated with HTLV-1 infection [17, 18]. A parathy-
roid-hormone-like substance has been implicated in the patho-
genesis of some cases of hypercalcemia [19]. When hypercal-
cemia does not resolve with conventional therapy with saline
and furosemide, the administration of mithramycin [18] or
calcitonin [17] can be effective. The parathyroid-vitamin D axis
remains to be carefully evaluated in patients with AIDS.
Hypouricemia was observed in 22% of 96 consecutive pa-
tients with AIDS [201. It was associated with a high fractional
Table 2. Causes of acute renal failure in AIDS patients
Prerenal azotemia
Acute tubular necrosis
Acute interstitial nephritis
Hemolytic-uremic syndrome
Thrombocytopenic purpura
Multiple myeloma
Acute glomerulonephritides
Obstructive uropathy
Rapidly progressive focal segmental glomeruloscierosis
excretion of uric acid even in volume-depleted patients. This
finding suggests abnormal renal tubular handling of uric acid.
More frequently, however, volume depletion is associated with
hyperuricemia.
Thus, electrolyte disorders in patients with AIDS can have
multiple and variable causes. Some electrolyte alterations result
from renal tubular functional defects, whereas others arise from
hormonal imbalances. In most instances, the various electrolyte
disturbances seen result from complications of AIDS.
Acute renal failure
All forms of acute renal failure can be observed in patients
with AIDS (Table 2). Acute renal failure can be related to
AIDS, its complications, or necessary diagnostic or therapeutic
interventions.
Acute renal failure occurred in 55% of 449 AIDS patients
admitted to Bellevue Hospital in New York City [21]. Causes
were volume depletion, 38%; pentamidine, 17%; amphotericin
B, 11%; trimethoprim-sulfamethoxazole (TMP/sulfa), 9%; sep-
sis, 8%; radiocontrast material, 4%; aminoglycoside antibiotics,
2%; other agents, 4%; and unknown, 7%. Prerenal azotemia,
the most common cause of an increased serum creatinine,
usually is due to dehydration and intravascular volume deple-
tion. If severe and prolonged, however, volume depletion can
lead to acute tubular necrosis with oligo-anuric renal failure.
Just as in patients without AIDS, nephrotoxic agents can be
responsible for acute renal failure and can add insult to injury.
Radiocontrast dyes and various antimicrobial agents used in
AIDS patients can cause acute tubular necrosis or acute inter-
stitial nephritis. Nonsteroidal antiinfiammatory drugs, in the
context of intravascular volume depletion, can decrease the
glomerular filtration rate dramatically [22].
Many of the drugs frequently required by patients with AIDS
are nephrotoxic [23]. Nephrotoxicity is the most common
complication of pentamidine given intramuscularly or intrave-
nously at the usual dosage of 4 mg/kg/day [24-26]. In patients
treated for longer than 7 days, an increase in serum creatinine
concentration greater than 0.5 mg/dl has been observed in 64%
[26] and greater than 2 mg!dl in 23% [27] of the patients. The
renal failure is usually transient, and renal function stabilizes
within 1 to 3 days of dosage reduction [26]. Uremia does not
develop unless other nephrotoxic events occur concurrently
[28]. The mechanism of nephrotoxicity is unknown [29, 30]. In
a minority of cases, transient hypotension, rarely clinically
significant, occurs at the time of rapid intravenous injection [26,
27]. Risk factors for renal failure include prolonged duration of
treatment as well as increased dosage and prior therapy with
pentamidine; these findings suggest that some of the toxicity
could depend on the cumulative amount of pentamidine bound
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to various tissues, including kidneys. Whereas some investiga-
tors recommend dosage adjustment at creatinine clearance
values less than 35 ml/min [28—31], others do not modify the
initial dosage of pentamidine for renal impairment but decrease
the dosage empirically by 30% to 50% when the serum creati-
nine increases by 1 mg/dl or more [26]. A single case report
describes acute renal failure resulting from myoglobinuria as-
sociated with pentamidine administration [32]. Trimethoprim-
sulfamethoxazole can produce acute interstitial nephritis, but it
appears to be less nephrotoxic than is pentamidine [25, 261.
When using various antibiotics, such as penicillins, cephalospo-
rins, aminoglycosides, or antituberculous agents in patients
with AIDS, one must closely monitor these patients' renal
function because frequently they are exposed to other nephro-
toxic agents and they can have preexisting renal insufficiency.
When the latter exists, dosage adjustments of these various
drugs are recommended for patients with decreased renal
function [33].
Renal insufficiency can be anticipated with the use of ampho-
tericin B, but ketoconazole, another widely used antifungal
agent, is not nephrotoxic. Foscarnet, a new antiviral agent, can
induce acute renal failure [35]. Gancyclovir is not nephrotoxic
[36, 37]. Acyclovir rarely increases serum creatinine, possibly
because it competes with creatinine for proximal tubular secre-
tion. Experimentally, after rapid intravenous administration,
acyclovir can crystallize in very concentrated tubular fluid.
Because acyclovir is excreted by the kidneys, retention is
prolonged in renal insufficiency. Dosage reduction to 200 mg
every 12 hours therefore is recommended by the manufacturer
in patients with creatinine clearances less than 10 mi/mm.
Azidothymidine is not directly nephrotoxic, but its prolonged
use can lead to rhabdomyolysis (Fischl M, personal communi-
cation); its association with acute renal failure has not been
reported.
In most patients with AIDS, drug-induced acute renal failure
is mild and can be reversed if the nephrotoxic agent is discon-
tinued. Unless acute renal failure is associated with overwhelm-
ing infection, respiratory or other organ system failure, or
massive proteinuria, severe hypoalbuminemia, and important
prerenal azotemia, recovery of renal function can be expected
in patients with AIDS. Supportive dialytic therapy sometimes is
needed temporarily before renal function recovers [39, 40].
A potpourri of other causes of acute renal failure is reported
in the literature. One patient with hemolytic-uremic syndrome
[411 and one patient with thrombotic thrombocytopenic purpura
[22] have been described. Multiple myeloma with IgA kappa
deposits has been reported [42]. Immune-complex glomerulo-
nephritis secondary to infection as well as other acute glomer-
ulonephritides also can be expected in this patient population
but have rarely been reported.
Acute renal failure from obstructive uropathy can occur in
AIDS patients in a wide variety of clinical settings, including:
(1) sulfadiazine-related crystalluria [43, 44]; (2) hyperuricosuria
secondary to chemotherapy in patients with AIDS-related lym-
phoma; and (3) retroperitoneal fibrosis [45] or ureteropelvic
infiltration in patients with lymphoma. The latter need not be
accompanied by hydronephrosis on ultrasonographic examina-
tion and may require retrograde urography for diagnosis.
Finally, azotemia is often the mode of presentation in patients
with nephrotic syndrome and a rapidly progressive form of
Table 3. Nephropathology in patients with HIV-1 infectiona
Autopsy Biopsy Total
Acute tubular necrosis 21 0 21
Interstitial nephritis 33 3 36
Nephrocalcinosis 46 0 46
Minimal-change disease 0 6 6
Mesangial hyperplasia 82 10 92
Focal segmental glomerulosclerosis 76 146 222
Other glomerulonephritides 6 11 17
a Values indicate number of times that a given finding is reported in
the literature [6, 46—74].
focal segmental glomeruloscierosis (FSGS) (see Patients 1 and
2). This form of renal failure, unlike other types of acute renal
failure, is characteristic of HIV-1-associated nephropathy and
frequently is seen before AIDS is diagnosed.
Nephropathology in patients with HIV-1 infection
The renal lesions found in patients with HIV- 1 infection vary
depending upon whether autopsy or biopsy specimens are
examined. Table 3 is a census from the literature. At autopsy,
the renal lesions most commonly observed are acute tubular
necrosis, interstitital nephritis, nephrocalcinosis, mesangial hy-
perplasia, and FSGS [6, 46—63] (Table 3). Renal invasion by a
variety of opportunistic pathogens (cytomegalovirus, candida,
cryptococcus, pneumocystis, nocardia, mycobacterium, histo-
plasma, toxoplasma, aspergillus, herpes) or neoplasms (carci-
noma, lymphoma, Kaposi's sarcoma, multiple myeloma) has
been variably íeported.
In contrast, renal biopsy in patients with HIV infection
(including patients with AIDS, patients with AIDS-related
complex, and asymptomatic HIV carriers) usually discloses a
glomerulopathy [39, 46—49, 53—57, 60—62, 64—74]. Focal segmen-
tal glomeruloscierosis was present in 83% of biopsies reported
in the literature, mesangial hyperplasia in 6%, minimal-change
disease in 3%, and other glomerulonephritides (including dia-
betic glomeruloscierosis and postinfectious, membranous, or
proliferative glomerulonephritis) in 6% (Table 3). Thus, for
autopsies and biopsies together, FSGS accounts for 51% and
mesangial hyperplasia for 21% of the nephropathology and for
66% and 27%, respectively, of the glomerular pathology re-
ported in patients with HIV-l infection (Table 3). The other
glomerulonephritides, including minimal-change disease, may
represent incidental findings. The greater frequency of glomer-
ular lesions at biopsy than at autopsy no doubt reflects the
selection bias for performing biopsies in patients with unex-
plained proteinuria. Similarly, the greater frequency of mesan-
gial hyperplasia at autopsy and of FSGS at biopsy stems from
the fact that mesangial hyperplasia rarely is clinically expressed
by more than modest proteinuria, and often is not associated
with a progressive decline in renal function [51].
HI V-associated nephropathy
We can define HIVN as the nonspecific but characteristic
glomerulopathy and tubulopathy developing in patients infected
with the human immunodeficiency virus. By convention, HIVN
to date includes only patients with heavy proteinuria (>2 g/24
hr) or with the nephrotic syndrome clinically and with FSGS
histologically. This definition is still in evolution, however,
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because patients with HIV-1 infection who have modest and
persistent proteinuria (<2 g124 hr), normal or minimally de-
creased renal function, and, histologically, diffuse mesangial
hyperplasia also may represent an early stage of HIV nephrop-
athy.
Let me reiterate that HIVN is not confined to terminally ill
patients with AIDS. More than 50% of patients with HIV-l
infection and nephrotic syndrome or FSGS are otherwise-
asymptomatic HIV-1 carriers or patients with ARC [40, 51, 53,
71—73, 75—77]. The nephropathy therefore may be an early
manifestation of HIV-1 infection and is therefore associated
with the HIV-l infection per se rather than with AIDS.
Clinical spectrum. Major manifestations of HIVN are pro-
teinuria and a reduction in renal function. The first manifesta-
tion of HIVN is proteinuria. In a prospective evaluation of 75
consecutive outpatients with AIDS, 32 (43%) excreted more
than 0.5 g of protein/24 hr and 7 (9%) had proteinuria in excess
of 3 g/24 hr [47]. Among 182 inpatients with AIDS, 85 (47%) had
proteinuria; 59 of these (32%) excreted more than 2 g of
proteinl24 hr [57]. In many centers, the incidence of heavy
proteinuria (that is, >2 g/24 hr) and/or FSGS among patients
with AIDS is 6% to 10% [39, 40, 54, 57, 67, 68, 78, 791.
In our first 100 nephrologic consultations on patients with
HIV-1 infection, we found these clinical features: (1) azotemia
(67%); (2) nephrotic syndrome (52%); (3) modest proteinuria
and a normal or slightly increased serum concentration of
creatinine (27%); and (4) macroscopic hematuria associated
with renal tuberculosis or glomerular disease (3%) [40]. These
percentages amount to more than 100% because some patients
belong to more than one category.
In 1984, HIVN was first reported in clusters of blacks in New
York and Miami [46—48]. To date, most patients live in metro-
politan areas in the eastern United States, including New York
[39, 48, 67, 68, 77, 78, 80], Boston [72], Newark [53], Washing-
ton, D.C. [59], and Miami [40, 54]. Individuals or small groups
of patients also have been identified in other cities, including
Cincinnati [65], San Francisco [62], Los Angeles [71], Detroit
[49], Dallas [6], and in other countries: Canada [55], Senegal
[70], the West Indies [64, 69], Trinidad [66], Mexico [52], Brazil
[50], and Spain [74]. Only one patient reported in the literature
is from Africa [70].
All groups at risk of HIV infection may be affected. The
prevalence of HIVN, however, appears to be distinctively
lower in white homosexuals than in other groups at risk [40, 61,
62]. In the United States, the ratio of white to black patients
with AIDS is 3 to I. Nevertheless, most patients with HIVN are
black. The reason for this apparent racial predilection is un-
known [81]. This observation probably accounts for the low
incidence of HIVN reported from San Francisco [61, 62] as well
as from Europe [82, 83].
Intravenous drug use has been cited as a major etiologic
factor in the development of HIVN [61]. It is clear, however,
that patients can develop HIVN even if they have not used
intravenous drugs. In large series, intravenous drug use was not
a risk factor for the majority of patients [39, 51]. Also, the
occurrence of HIVN in children with perinatal AIDS strongly
argues against intravenous drug use as a necessary risk factor
[51, 53—55, 58, 71]. Further, even after intravenous drug users
are excluded from consideration, an 8 to 1 ratio of HIVN in
blacks versus whites remains among published cases [81].
Table 4. Pathologic characteristics of HIVN
Light microscopy
Glomeruli and interstitium
Early: Mesangial hyperplasia
Interstitial infiltrate
Advanced: Reactive visceral epithelium
"Collapsed" capillaries
Dilated Bowman's space
Scanty interstitial infiltrate
Tubules: Tubular "simplification"
Microcystic dilations
Giant variegated casts
Immunofluorescence
Mesangial 1gM, C3, Cl
Immunoglobulins/albumin in visceral epithelium, Bowman's space,
and casts
Electron microscopy
Foot process effacement
Wrinkled glomerular basement membrane
Mesangial dense deposits
Endothelial tubuloreticular inclusions
Tubular and interstitial nuclear bodies and chromatin degeneration
Peripheral edema can be conspicuously absent in patients
with AIDS even when they have nephrotic-range proteinuria
and severe hypoalbuminemia [68, 77—791. Dehydration and low
blood pressure as a result of chronic diarrhea, and/or malnutri-
tion/malabsorption can induce intravascular volume depletion
and hence may prevent accumulation of fluid in interstitial
tissue. For the same reasons, hypertension is often absent, even
in patients with advanced renal insufficiency [40, 46, 49, 68,
77—79].
The diagnosis of HIVN relies on a high degree of clinical
suspicion, evaluation of possible risk factors, exclusion of other
causes of proteinuria and/or renal insufficiency, confirmation of
HIV-1 infection, and ultimately renal biopsy. Ultrasonographic
examination of the kidneys is useful. Typically, the renal
echogenicity in patients with HIVN exceeds that of the liver.
The kidneys' increased echogenicity has been attributed to
nephrocalcinosis [84] and tubular abnormalities [85] present in
HIVN (described later). Kidneys in patients with HIVN are
normal-sized or frankly enlarged [49, 51, 77, 84]. Renal size
does not correlate with the degree of proteinuria [40].
In patients with nephrotic-range proteinuria, HIVN progres-
sion toward end-stage renal disease is rapid, occurring within an
interval of weeks to months [39, 46—49, 53, 54, 67, 68, 77—79].
Rapid progression of renal disease, however, is not a universal
finding [51, 57, 62]; the clinical course can be indolent, partic-
ularly in patients with minimal proteinuria until the nephrotic
syndrome develops, as in the second patient presented today
[51].
Pathology. Glomerular and tubulointerstitial damage charac-
terize the FSGS of HIVN (Table 4). It might be that FSGS is
preceded by another stage of lesser glomerular involvement,
such as mesangial hyperplasia and/or minimal-change disease.
This possibility is dictated by the inordinately high frequency
with which mesangial hyperplasia is observed in patients dying
of AIDS. Thus, one can speculate that the renal manifestations
in HIVN begin with modest proteinuria, normal or minimally
decreased renal function, and normal-sized kidneys complicat-
ing mesangial hyperplasia. Presumably, nephrotic syndrome
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Fig. 1. Glomerulus with diffuse mesangial hyperplasia. The interstitial infiltrate is abundant. Tubules have cell debris in the lumina.
Fig. 2. "Collapsed" glomerulus with prominent visceral epithelial cells and dilated Bowman's space filled with proteinaceous material. Dilated
tubules with variegated casts are prominent.
evolves next, and the late stage includes rapidly progressive,
irreversible renal failure complicating FSGS. In support of this
hypothesis, we have observed two nephrotic patients (one of
them an HIV carrier) in whom renal biopsy revealed diffuse
mesangial hyperplasia. Autopsy disclosed FSGS in one of
them.
This sequential evolution is not universal, however. Patients
with nephrotic-range proteinuria, particularly children, may
exhibit only glomerular mesangial hyperplasia on biopsy [53,
54, 58]. Also, "silent" FSGS can be found in autopsy speci-
mens from patients with only modest proteinuria and normal
renal function [52, 55, 56]. Finally, Macaccus rhesus monkeys
inoculated with simian immunodeficiency virus develop glomer-
ular mesangial hyperplasia or a scierosing glomerulopathy with
an equal frequency [871.
Mesangial hyperplasia in AIDS patients has been confirmed
in adults [6, 39, 48, 50—52] and in children [53, 54, 58] with
HIV-l infection. Nevertheless, it has not been systematically
observed [60, 71, 80]. Rather, Chander and coworkers [80]
describe the glomerular mesangium as hypocellular in adults
with HIV-l infection. This hypocellularity can be present at a
later stage of the nephropathy [511.
Minimal-change disease also has been associated with HIV- 1
infection [54, 56, 60, 64, 74]. As Table 3 indicates, minimal-
change disease is rare and might be coincidental or the result of
non-representative tissue biopsy sampling. Nevertheless, pro-
gression from minimal-change disease to FSGS in the same
patient has been reported [60]. Characterization of the possible
pathogenetic link between minimal-change disease or mesangial
hyperplasia and FSGS in HIV-l infection must await further
observations.
The characteristic features of FSGS in HIVN are qualita-
tively similar to those observed in other forms of FSGS,
including the idiopathic variety and FSGS associated with
heroin abuse. Quantitatively, however, FSGS in HIVN appears
histologically much more aggressive in its glomerular and
tubulointerstitial manifestations [47, 60, 71, 80]. At autopsy,
kidneys from patients with HIV-1 infection and FSGS usually
are enlarged, weighing 50% to 100% more than normal kidneys
or kidneys with mesangial hyperplasia [51].
In early lesions of HIVN, mesangial hyperplasia predomi-
nates, and changes of FSGS are minor [51]. The interstitium
usually contains a marked infiltrate of lymphocytes and plas-
macytes [50, 51, 60] (Fig. 1). In established lesions of FSGS, the
visceral epithelial glomerular cells appear hyperplastic and
hypertrophic, with conspicuous vacuoles containing protein
droplets [51, 60, 71, 80]. Capillary lumina in affected areas are
narrowed with [71] or without [60] segmental increases in the
mesangial matrix. The interstitial infiltrate can be abundant with
areas of interstitial fibrosis and tubular atrophy [51]. In the
advanced stage of FSGS, the glomerular capillary obliteration is
diffuse and global. Glomeruli are "collapsed," reduced to
stumps, and are often crowned by a row of hypertrophic
visceral epithelial cells [51, 60, 71, 80]. Bowman's space fre-
quently appears dilated and filled with proteinaceous material
[51, 60, 71, 80]. The infiltrate can be scanty in an interstitium
that frequently appears edematous and replaced by a homoge-
neous acidophilic substance [51, 80] (Fig. 2). Lesions of vari-
able severity can be identified in the same biopsy specimen.
Tubular changes are always prominent in established lesions.
Focal tubular degenerative changes or necrosis at various
stages of evolution can be present in the absence of an identi-
fiable nephrotoxic or hemodynamic insult. Tubular epithelial
cells appear flattened, "simplified" with loss of nuclei and
brush border [51, 60, 71, 801. Tubules often are markedly
dilated or microcystic, and they are filled with giant variegated
casts [51, 60, 71, 80] (Fig. 2).
By immunofluorescence, deposits of 1gM and C3 [51, 60, 71,
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801 and Cl [60, 71] are identified in the mesangium and
peripheral capillary wall. The same deposits can be identified in
HIV-1 patients with normal glomeruli on light microscopic
examination [47, 51]. Visceral epithelial cells stain for immuno-
globulin and/or albumin in areas corresponding to the intracel-
lular droplets identified by light microscopy [60, 71]. The large
tubular casts have not been reported in urinary sediment. These
casts may be occlusive and responsible for kidney enlargement
[71]. They contain immunoglobulins, light-chain protein, albu-
min, and fibrin but not Tamm-Horsfall protein [71].
Ultrastructural changes in HIVN include pronounced foot-
process effacement [60, 71, 80], wrinkling and folding of the
glomerular basement membrane, collapsed glomerular seg-
ments, and dense deposits in the mesangium [51, 60, 71, 80]
and, more rarely, in subendothelial and/or subepithelial areas
[60]. Numerous tubuloreticular inclusions (involving the gb-
merular and peritubular capillary endothelium) and interstitial
leukocytes are present [60, 71—73, 80, 88], as well as nuclear
bodies and granular degeneration of tubular and interstitial cell
nuclear chromatin [60, 80].
None of these renal manifestations is specific for HIVN.
Their combined presence, however, is highly characteristic [51,
60, 71, 80]. We have been impressed by our nephropathobogist's
ability to make presumptive diagnoses of HIV- 1 infection that
ultimately proved correct in patients not suspected of having
retroviral infection. The same experience has appeared in the
literature [71].
Several studies have compared the FSGS of HIVN with that
of heroin-associated nephropathy [60, 71, 80, 88]. The concen-
sus is that distinctive pathologic features of HIVN include: (1)
the "collapsing" and predominantly global pattern of glomeru-
lar sclerosis; (2) the severity of visceral epithelial cell hypertro-
phy and droplet formation; (3) the prominent tubular microcysts
and cast formation; (4) the focal tubular degenerative features;
and (5) the numerous tububoreticular inclusions in renal endo-
thelium and infiltrating leukocytes. This ultrastructural marker
of HIVN can be seen before the development of AIDS [60, 88]
as well as in HIV-l-infected patients without HIVN. Tubulore-
ticular inclusions therefore are a general feature of HIV-1
infection and are not specific for HIVN per se [60]. An
increased number of type-Ill [60, 801 and type-V [73] nuclear
bodies and an increased fibrillogranular transformation of the
nuclear chromatin in tubulointerstitial cells [73, 80] are charac-
teristic of HIVN for some, but not all [71, 88], nephropatholo-
gists.
Patho genesis. The pathogenesis of HIVN is unknown. op-
portunistic infections do not explain the glomerulopathy, as
HIVN frequently occurs in HIV carriers and in patients with
ARC. There is little evidence of an immunologic origin. Circu-
lating immune complexes are frequent in AIDS patients, but
mesangial deposits can be present whether or not clinical renal
disease is overt [47, 51]. Immune-complex nephritis is uncom-
mon and possibly reflects the altered immune state of these
patients [61].
Focal segmental glomerulosclerosis represents a pattern of
glomerular reaction common to many apparently unrelated
clinical entities, including aging, systemic hypertension, diabe-
tes mellitus, sickle-cell disease, reflux nephropathy, obesity,
intravenous drug use, and unilateral renal agenesis. Experimen-
tally, FSGS can be induced by partial renal ablation in rodents.
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The events initiating the characteristic mesangial cell and
glomerular transformations are unknown. Nevertheless, the
kidney reacts with a common type of inflammatory response
including mesangial cell proliferation, FSGS, and ultimately
glomerular obsolescence [89]. A current belief is that FSGS
represents a hemodynamic glomerulopathy that develops as a
result of primary or compensatory intraglomerular hemody-
namic alterations. By analogy, one can speculate that HIVN is
also of hemodynamic origin and possibly is mediated by local
lymphokines and/or factors of mesangial proliferation with
activity on glomerular capillary permeability. No direct exper-
imental evidence exists to support or refute this hypothesis.
Alternatively, we can postulate direct pathogenic mecha-
nisms. Infected blood-borne lymphocytes or monocytes/macro-
phages could disseminate HIV-1 to the kidney or could directly
infect renal cells bearing the CD4 antigen receptor as well as
subpopulations of monocytes/macrophages. Activation of
monocytes/macrophages in the kidney could spread HIV- 1 to
other cell populations. The accumulation of viral antigen then
would produce an inflammatory response that would mediate
the destruction of renal tissue. If HIV-1 proves renotropic, the
kidney might serve as sanctuary for the virus (Fig. 3).
Antibodies to HIV-1 [90], but not HIV-1 antigens [91], have
been isolated from the urine of patients with HIV-l infection.
To date, however, no direct evidence demonstrates a causal
relationship between HIV-l in the kidney and renal disease.
Arguments supporting HIV- 1 localization in the kidney include
the following: (1) In patients who have had a renal transplant,
infection of the recipient with HIV-l has been traced to the
cadaver donor kidney [92—99]. Infection by this route might
imply the presence of HIV- 1 within parenchymal cells of the
transplanted kidney. (2) Precedent exists for the kidney to serve
as sanctuary for a virus. Transmission of cytomegalovirus by
renal transplantation indicates that renal cells can harbor latent
viruses. Cytomegalovirus can infect and replicate in vitro in
gbomerular mesangial cells in culture [100]. Thus mesangial cells
might be a primary target for certain viruses. (3) T-lymphocytes
and monocytes/macrophages expressing the CD4 molecule are
the primary receptor cells for HIV-1. In these cells, the CD4
antigen is the membrane receptor for the envelope glycoprotein
(gp 120) of HIV- 1. Bone-marrow-derived cells, representing 3%
to 5% of total glomerular cells, have been demonstrated in the
gbomerular mesangium of rodents [101]. Recent immunohisto-
chemical studies using monoclonal antibodies against the CD4
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Fig. 3. Possible pathogenesis of HJVN.
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molecule demonstrated the presence of CD4 antigen in mesan-
gial cells of normal human kidneys [102]; these studies suggest
that direct HIV-l infection of glomerular cells expressing CD4
might be possible. Because HIVN develops only in a minority
of patients, factors that modulate the susceptibility of such cells
to HIV-l infection also must be involved [1021. (4) Using an
anti-core P24 monoclonal antibody, Cohen and coworkers
localized HIV-l core P24 antigen in distal tubular epithelial cells
[103]. Moreover, by in-situ hybridization, and using a cDNA
probe for HIV-l nucleic acid, these researchers found the
HIV- 1 genome in proximal and distal tubular epithelial cells and
in glomerular visceral and parietal epithelia in each of 10 renal
biopsies from patients with HIVN. Their report suggests that
direct viral infection of renal tissue is possible. This observation
needs confirmation. (5) No adequate animal model has been
developed for HIV-l-induced disease. Chimpanzees can be
infected and seroconverted but do not become sick [104]. On
the other hand, macaque monkeys inoculated with simian
immunodeficiency virus (SlY) strains might provide a relevant
model for the study of HIVN.
Although more closely related to HIV-2 (the West African
isolate) than to HIV-1, Sly strains cause a disease in macaques
that is characterized by weight loss, opportunistic infections,
and depletion of CD4-positive lymphocytes; the clinical spec-
trum resembles AIDS in humans in various respects [104]. In
one study, 4 of 6 macaque monkeys inoculated with SIV died.
Interestingly, one of them had severe interstitial nephritis and
FSGS [1041. In another study, 19 rhesus monkeys were inocu-
lated with SlY; at autopsy, 5 had developed a scierosing
glomerulopathy; another 5 had mesangial hyperplasia [87].
These findings suggest not only an association between SIV and
glomerular sclerosis but between SIV and mesangial hyperpla-
sia. Moreover, in 7 monkeys, focal tubular dilation and cast
formation were also present [871.
Baboons also can be infected by SIV strains. Like the
macaque and rhesus monkeys, they develop lymphadenopa-
thies, but they do not seroconvert and they remain healthy.
Their lymphocytes express CD4 receptors. These differences
indicate that resistance in vivo cannot simply be attributed to
the inability of lymphocytes to bind and be infected by STY.
Other factors influencing viral replication or host resistance,
possibly of genetic origin, might modify expression of disease
[104].
Treatment. No therapy has proved effective for FSGS or
HIVN. Several patients with nephrotic syndrome, including
children, were treated with corticosteroids without success
[54]. Azidothymidine has not been tried prospectively in pa-
tients with HIVN. If HIVN is due to HIV replication and if
FSGS is the end-stage form of a progressive nephropathy (as
was possible in Patient 2), one can speculate that azidothymi-
dine might retard or attenuate the explosive form of FSGS in
HIVN. Such a therapeutic trial should be undertaken in patients
with modest proteinuria before renal function is markedly
decreased. In our experience, however, azidothymidine admin-
istration to patients with Pneumocystis carinii did not prevent
the subsequent development of HIVN in some of those pa-
tients.
Supportive dialytic therapy has been used in patients with
HIV infection and renal failure. Temporary hemodialysis per-
mits recovery of renal function in patients with AIDS and
reversible acute renal failure and thereby extends patient sur-
vival [39, 40]. In HIV-l carriers and in patients with ARC and
irreversible renal failure secondary to HIVN or other diseases,
chronic hemodialysis provides many months to years of sur-
vival [105]. In contrast, chronic hemodialysis does not rehabil-
itate the patient with AIDS. In general, after AIDS is diag-
nosed, survival in the patient with chronic renal failure is dismal
and rarely exceeds one month despite the continuation of
hemodialysis [22, 39, 105].
Questions and answers
Da. IRWIN M. ARIAS (Chairman, Department of Physiology,
Tufts University School of Medicine, Boston, Massachusetts):
Weissman at Stanford has injected human fetal thymus, spleen,
and bone marrow into SCID (severe combined immunodefi-
ciency mice) and produced a human/mouse hybrid. The entire
hematopoietic and immune systems are of human origin in these
mice, which do not reject such implantations. Are you aware
that SCID mice have been infected with HIV and, I believe,
that some have developed tissue injury? It is possible that the
human hybrid SCID mouse infected with HIV may provide a
model of renal injury.
DR. BOURGOIGNIE: I was not aware of these findings. They
may be interesting, indeed, as a model of HIV-associated
nephropathy.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Do you
have any thoughts on why nephropathy might be so rare in
homosexual whites?
DR. BOURGOIGNIE: This is an important question without an
answer to date. Although rare, HIVN in white homosexuals
does exist. This observation suggests that cofactors operate in
the expression of HIVN. Race, rather than homosexuality,
might be the important variable. We have seen HIVN in black
homosexuals. In the world literature, 116 blacks and 16 whites
with FSGS and HIV infection are reported. Of these, 32 blacks
and 6 whites were intravenous drug users. After exclusion of
intravenous drug users, 84 blacks and 10 whites (a ratio of 8/1)
remain with HIVN and other risk factors for HIV infection; this
suggests that intravenous drug use does not explain the larger
number of blacks than whites with HIYN. My impression is
that HIVN generally may be more rarely expressed in white
than in black patients with any risk factors for HIV infection.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center): You
mentioned the supposition that the mesangial hyperplasia even-
tually evolves into focal sclerosis. How much data are there
from biopsies of patients who have had mesangial hyperplasia
and who have gone on later at autopsy or subsequent biopsy to
have developed focal sclerosis?
Da. BOURGOIGNIE: The progression that I described remains
hypothetical. I know of at least 2 patients with mesangial
hyperplasia on renal biopsy who had FSGS at autopsy. More
data are needed. Renal biopsies should be obtained in patients
with modest proteinuria to define the early nephropathy in
patients with HIV infection.
Da. MADIAS: In contrast to biopsies, your autopsy material
showed substantial interstitial disease. Do you think that this
might be a consequence of drug therapy or terminal sepsis?
DR. BOURGOIGNIE: Quite possibly. In some patients, inter-
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stitial disease might be drug related. Patients coming at autopsy
are patients with AIDS who have been exposed to a number of
drugs. On the other hand, they also have been exposed to
various opportunistic infections.
Da. DAVID CAHAN (Department of Nephrology, Faulkner
Hospital, Boston, Massachusetts): I would like to describe to
you a patient I first saw in early 1986. I think she is interesting,
and I would appreciate your comments on the clinicopathologic
correlation that we identified.
This patient, a 30-year-old black woman, presented with a
serum creatinine in the range of 8 to 10 mgldl. Apparently, her
serum creatinine had been about 2 mgldl several months prior to
presentation. She had non-nephrotic proteinuria and diffuse
adenopathy; on histologic examination of her bone marrow,
lymph nodes, and kidney, there was massive infiltration by
mature plasma cells. Renal biopsy did not reveal significant
glomerular involvement. She had a high level of gamma globu-
lin, and careful study of her plasma cells revealed that they
were polyclonal in nature. She did not respond to a short course
of high-dose steroid therapy and required chronic hemodialysis.
She survived for 3 years. Her initial CD-4ICD-8ratio was very
low, and approximately one year before her death she devel-
oped a positive HIV titer. She succumbed to cryptoccocal
meningitis. On evaluating her renal biopsy, it appeared to us at
that time that the dense interstitial infiltrate represented a
reaction to one or more unidentified antigens. We later found
out that she was associated with drug addicts and it was likely
that she was a drug addict herself. I wonder whether you have
encountered similar cases, and I would appreciate your com-
ments on this particular patient.
Da. BOURGOIGNIE: I have not seen a similar patient. She
didn't have multiple myeloma?
DR. CAHAN: No. In fact, I wonder whether some of the cases
of myeloma that you mentioned might actually represent some-
thing akin to what our patient might have had.
DR. BOURGOIGNIE: The case that I was referring to from
Australia [42] was a 29-year-old homosexual with a lymphade-
nopathy syndrome who was admitted with acute renal failure.
This patient had multiple myeloma with a dense monoclonal
IgA kappa paraprotein, 90% abnormal plasma cells in the bone
marrow, and lytic lesions in several bones. The renal failure
abated after chemotherapy with melphalan and prednisone. The
association between HIV infection and B-cell proliferation has
been demonstrated [106]. Your patient might be another exam-
ple.
DR. RONALD PERRONE (Division of Nephrology, New Eng-
land Medical Center): You mentioned that there have been no
reported cases from Africa. Is this a function of lack of data or
of good data and no cases?
DR. BOURGOIGNIE: This is a function of lack of data. Let me
add, however, that several black patients from Zaire with HIV
infection and a nephrotic syndrome have been treated in
Belgium. Renal biopsy in these patients disclosed FSGS (van
Ypersele de Strihou, personal communication). I also recently
learned from Dr. E. Kioko of the Nairobi Hospital, Nairobi,
Kenya that heavy proteinuria was not an uncommon finding in
the AIDS population in Nairobi. Renal biopsies, however, were
not obtained in these patients.
Da. PERRONE: I think that that is important. Indeed, trans-
mission of AIDS via a purely heterosexual route was evident in
Africa a long time before it was definitively established here.
Are we sure that the increased prevalence in blacks is not
simply a socioeconomic phenomenon? For example, were more
untreated hypertension in blacks and better medical care in
white homosexuals responsible for the difference in the appar-
ent prevalence of HIVN in blacks?
DR. BouRGoGNIE: Clearly the two populations are different.
Both, however, are young—between 17 and 40 years old—and
are not hypertensive. I can't tell you why HIVN seems to be
more prevalent in blacks. Is it a socioeconomic phenomenon? I
doubt that it is.
DR. KASSIRER: Given the fact that these patients with AIDS
develop a variety of renal diseases (some of which are revers-
ible), what are the clinical clues that make us suspicious that we
are dealing with focal sclerosis or mesangial hyperplasia? What
does the urine sediment show in patients who have mesangial
hyperplasia or focal sclerosis?
DR. BOURGOIGNIE: Heavy proteinuria suggests FSGS. The
urinary sediment is otherwise nonspecific. Many patients have
pyuria as a result of urinary tract infection. Microscopic hema-
tuna is seen, but red cell casts are unusual. The large protein
casts seen on renal biopsy are not apparent in the urinary
sediment.
Da. KASSIRER: Are there other clinical features that should
raise the possibility of HIVN?
DR. BOURGOIGNIE: A high level of clinical suspicion is
necesary with any young adult, man or woman, without a
medical history of renal disease, who presents with heavy
proteinuria, usually with an increase in serum creatinine, in the
absence of or with modest hypertension. This is particularly
true if constitutional symptoms (unexplained weight loss, fever,
diarrhea) exist and if the kidneys are large by ultrasonography.
DR. MADIAS: Given what we know about the function of the
normal glomerulus, can we develop a hypothesis on why
generic immunodeficiency might lead to mesangial hyperplasia
and subsequently to focal sclerosis?
DR. B0uRG0IGNIE: We have in HIVN an extraordinary
opportunity to study the pathogenesis of focal segmental gb-
meruloscierosis. I do not believe that immunodeficiency per se
leads to FSGS. First, in many HIV-infected patients, FSGS
develops before immunodeficiency is clinically important. Sec-
ond, FSGS is rare after renal transplantation, that is, in chem-
ically immunosuppressed patients. Whether HIV per se or
other factors are responsible is currently unknown. We plan on
using different types of renal cells grown in homogenous
cultures to determine which specific glomerular cell type can be
infected with HIV and what the consequences of infection
might be on cell metabolism.
DR. JEANINE CAnison (Division of Nephrology, New Eng-
land Medical Center): Although HIV nephropathy is the most
likely diagnosis in an HIV-positive patient with nephrotic
syndrome, some of these patients may have other forms of
glomerulonephritis. Could you comment on the risks of therapy
in these patients who are HIV-positive and who have another
type of glomerulonephritis, such as membranous glomerulone-
phritis? Specifically, do you treat them as you would otherwise
treat patients who have glomerubonephritis alone, or do you
recommend adjusting your therapy in any way because they are
HIV positive?
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DR. B0uRG0IGNIE: Several patients believed to have lupus
but who turned out to have HIVN were conventionally treated,
with steroids particularly, apparently without harm but also
without benefit. Several patients also have been described who
became HIV infected after renal transplantation. These patients
did not develop HIVN despite maintenance of their immuno-
suppressive drugs. We have no experience of an HIV patient
with a type of glomerulonephritis other than FSGS, for whom a
specific form of therapy might have been indicated.
DR. MADJAS: What has been the impact of this flood of AIDS
patients on your dialysis unit in terms of its overall function and
daily procedures?
DR. B0uRG0IGNIE: We currently operate on a routine basis
with 20% to 25% of our chronic hemodialysis patients seropos-
itive for HIV. Three or 4years ago, nurses, fellows, and faculty
members were uneasy about dialyzing AIDS patients and about
the presence of HIV-seropositive patients in the chronic dialy-
sis unit. Since then, recognition that HIV is not as readily
transmitted as hepatitis B, and that precautions in use against
transmission of hepatitis B were protective against HIV, alle-
viated personnel fears. Standard precautions applied against the
transmission of hepatitis B have been reinforced. More atten-
tion is given to the details of hemodialysis, at the way table tops
are cleaned, needles are handled, etc. Universal precautions are
applied. Separate machines and separate geographic areas are
not used for HIV-seropositive patients, unlike for hepatitis
B-seroantigen-positive patients. In a study ongoing since 1986,
we have found no evidence of HIV transmission among our
chronic hemodialysis population [107].
DR. MADIAS: Has there been any evidence that treatment of
AIDS has changed the pattern or the prognosis of HIVN?
DR. BOURGOIGNIE: There has been no report of prospective
treatment with antiviral agents of patients who have HIVN. We
have seen patients who received AZT because of Pneumocystis
carinii infection. Some of these patients later developed HIV
nephropathy. Because the nephropathy is rapidly progressive
once heavy proteinuria exists, a prospective trial, with AZT for
instance, should involve patients with modest proteinuria and a
minimal decrease in renal function.
DR. ANDREW LEVEY (Division of Nephrology, New England
Medical Center): In contrast to the dismal survival of patients
with AIDS treated with dialysis, your data demonstrate pro-
longed survival in some patients with asymptomatic HIV infec-
tion and AIDS-related complex treated with dialysis. These
data demonstrate the importance of severity of disease on the
outcome of dialysis therapy. A similar question arises regarding
renal transplantation. In patients with AIDS, the prevalence of
severe opportunistic infections and short life expectancy would
seem to preclude transplantation in most cases. However, in
most transplant centers, patients with less severe infection are
also excluded from transplantation. I am not convinced that this
policy is appropriate. Are you aware of data regarding kidney
transplantation in patients with asymptomatic HIV infection or
with AIDS-related complex, and what is the policy in your
dialysis unit?
DR. B0uRG0IGNIE: Today, our surgeons will not perform
transplantation in an HIV-seropositive recipient. We have
experience with 4 patients who between 1982 and 1986 became
HIV infected during the perioperative period. We measured
HIV-1 antigen and antibodies retrospectively in frozen serum
samples. The same pattern was evident in all. Within one month
after transplantation, the HIV antigen became detectable in the
serum. Antigen then disappeared as HIV antibody titers be-
came detectable [108].
DR. LEVEY: Do you know the source of the virus?
DR. B0uRG0IGNIE: No. Infection occurred during the pen-
operative period from the donor kidney itself or from blood
transfusions. A pretransplantation transfusion protocol is used
at our institution. The outcome of these patients was as follows.
One patient died with full-blown AIDS and a functioning graft
despite discontinuation of all immunosuppressive drugs [109].
Two patients rejected the transplanted kidneys while on immu-
nosuppressive therapy and now undergo chronic hemodialysis;
they are asymptomatic 4 and 7 years after HIV infection was
documented. The fourth patient remains asymptomatic with a
functioning graft 5 years after transplantation. Similar patients
can be found in the literature. Some surgeons will transplant a
kidney into an HIV-seropositive carrier. Most will not. This
perspective, however, is evolving as data become available.
DR. MADIAS: Are the patients who received transplants
under regular immunosuppressive regimens?
DR. BOURGOIGNIE: Yes.
DR. LEVEY: I would like to add another case to your
experience. We cared for a young woman with renal failure due
to insulin-dependent diabetes mellitus. Six months after initia-
tion of dialysis, she received a living-related transplant and did
very well. One year later, during pregnancy, she developed
neutropenia, and azathioprine was withheld. After delivery she
had an episode of acute cellular rejection that reversed with
additional immunosuppressive therapy. Approximately one
year later, the baby died from AIDS. The mother (our patient)
was also found to have antibodies to HIV, and in retrospect,
tests on stored sera demonstrated that she had antibodies to
HIV at the time of transplantation, presumably acquired from
blood transfusions she received while on dialysis. Her first
opportunistic infection was 2 years later (4 years after trans-
plantation). She has now succumbed to the disease. Although
she and her child died from HIV infection, during the first 4
years after transplantation, she was much better rehabilitated
than she was during her 6 months on dialysis.
DR. PAUL KURTIN (Chief, Division of Pediatric Nephrology,
New England Medical Center): Adrenal insufficiency has been
well described in patients with AIDS. How many of your
patients with hyponatremia and/or hyperkalemia had adrenal
insufficiency?
Da. B0uRG0IGNIE: I have no personal data to answer your
question. Nephrologists are not often called to evaluate hy-
ponatremia at our institution. Many electrolyte problems are
solved at residents' report.
DR. KURTIN: We reported a patient with AIDS who had a
seizure secondary to hyponatremia following a tap-water en-
ema. The patient was subsequently found to have adrenal
insufficiency [1101. An association between HLA-Bw53 in black
drug abusers and focal sclerosis has been described [111]. Are
you aware of any HLA studies in blacks versus whites with
AIDS?
DR. BOURGOIGNIE: No. I am not aware of any study in blacks
versus whites with AIDS or with HIVN. This might be an
interesting question to study, for a "molecular mimicry" has
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been recently described between HIV-1 and HLA class-IT
antigens [112].
DR. PERRONE: Your comment about the prevalence of the
nephropathy in asymptomatic patients would lead one to think
that this should be added to the causes of idiopathic nephrotic
syndrome and/or non-nephrotic proteinuria. Under what cir-
cumstances would you get an HIV test as part of the workup of
proteinuria or nephrotic syndrome?
DR. B0uRG0IGNIE: In Miami, this is part of our systematic
workup of a nephrotic patient.
DR. HOWARD C0RwIN (Division of Nephrology, New En-
gland Medical Center): Have you employed peritoneal dialysis
in any of these patients? Can you retrieve the virus from
peritoneal fluid?
DR. BOURGOIGNIE: We do not have a CAPD program and
therefore have no experience with peritoneal dialysis in HIV-
infected patients. The literature indicates, however, that HIV
antigen can be identified in peritoneal fluid, and that peritoneal
fluid therefore might be potentially infectious [113].
DR. CoawiN: Is the virus isolate viable?
DR. B0uRG0IGNIE: I do not know.
DR. PAUL SKOLNIK (Division of Geographic Medicine and
Infectious Diseases, New England Medical Center): There is a
difference between finding HIV- 1 antigen and detecting infec-
tious virus. In fact, I have examined close to 50 urine samples
looking for infectious HIV-1 and have not detected any repli-
cation-competent HIV [114]. These samples are from HIV-l
seropositive patients, some of whom have AIDS nephropathy
and others who had hematuria and pyuria. Eighty-five percent
of these individuals were viremic at the time of culture. I
suspect that urea, which inactivates most retroviruses, might be
inactivating HIV within urine. It seems clear from a number of
studies, some of which were presented by Dr. Bourgoignie, that
HIV- 1 or P24 antigen can be detected by immunohistochemis-
try within renal parenchymal cells. The virus itself may well be
present in renal cells, but whether infectious virus is present in
urine is an entirely different question.
DR. BOURGOIGNIE: How would you differentiate between
infectious and noninfectious?
DR. SKOLNIK: Infectious virus will replicate in tissue culture.
I should add that I would still recommend universal precautions
for handling all bodily fluids, because we cannot exclude with
complete certainty the presence of infectious HIV (or other
transmissible agents) in all urine samples, especially those that
are grossly bloody. Also, the absence of infectious HIV in urine
does not exclude the possibility that HIV is important in the
pathogenesis of renal disease in HI V-infected patients. In fact,
I think it probably is.
DR. BouRGoIGNrn: Let me emphasize Dr. Skolnik's call on
precautions. We now have evidence that there may be more
than one retrovirus in the dialysis population in Miami. We
know about the infectivity of HIV- 1. We do not know about the
infectivity of other retroviruses. In our chronic dialysis popu-
lation, 8 of 129 patients carry a retrovirus other than HIV-1,
either HTLV-l or HTLV-2 [115].
DR. KASSIRER: Dr. Skolnik, what was your reason for think-
ing that the HIV itself might be pathogenic with respect to the
renal lesion?
DR. SK0LNIK: Just for the reasons that were enumerated
earlier in terms of the presence of HIV-l antigen and HIV
genomic equivalents within the renal parenchyma itself. This is
clearly only an association, but studies to assess pathogenic
significance should certainly be carried out.
Reprint requests to Dr. J. Bourgoignie, Division of Nephrology,
University of Miami School of Medicine, P.O. Box 016960 (R126),
Miami, Florida 33101, USA
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